| Drug Name: | Bunazosin (80755-51-7) |
|---|---|
| PubChem ID: | 2472 |
| SMILES: | CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC |
| InchiKey: | RHLJLALHBZGAFM-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 373.457 |
| LogP | : | 2.068 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 93.81 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Rifampicin (13292-46-1) | Reduced Bunazosin Serum Levels | Antagonistic | Rifampicin increases the metabolism of bunazosin by the liver | 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer |
| Enalapril (75847-73-3) | Bradycardia | Antagonistic | Selectivity for alpha receptors in the prostate. | Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha 1-blocker |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|